Tempest Therapeutics, Inc. (TPST)
TPSTNASDAQ-CMBiotechnology: Pharmaceutical Preparations
$0.4000
+0.0194 (+5.10%) today
Closed, Nov 9, 4:00 PM ET
- Market cap
- $7.23m
- P/E
- –
- EPS, last 4 quarters
- $-2.26
- Dividend yield
- –
- Day range
- –
- 52-week range
- $0.3706 to $10.33
- Average volume
- 3.18m
- Previous close
- $0.3806
Analysts
1 coveringBuy1 buy, 0 hold, 0 sell
Targets a year out average $7.00, +1650.0% from here
Earnings
next estimate $-0.3200Next report Nov 11, 2026
Sep 2025
+75.8%
Dec 2025
0.0%
Mar 2026
-82.1%
Jun 2026
-13.3%
estimate reported, and the surprise
Financials
| Quarter | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| Revenue | – | – | – | – |
| Gross profit | – | – | – | – |
| Operating income | -$3.60m | -$4.08m | -$27.72m | -$5.25m |
| Net income | -$3.51m | -$4.02m | -$27.70m | -$5.24m |
News
8 latest- Tempest Therapeutics Receives Nasdaq Notice of Bid Price Below $1.00Fintel · 4 days ago
- Biotech Stocks See Fresh Catalysts: Tempest, DataMEDS, NeurAxis & MAIA RTTNews · Sep 16, 2026
- Tempest Gets Option To License CD7-Targeted In Vivo CAR-T Platform; Overnight Stock Surge 64% RTTNews · Sep 15, 2026
- Tempest Announces $2.5 Mln Private Placement, Stock Down RTTNews · Sep 11, 2026
- Tempest Q2 Loss Narrows; Advances In Vivo CAR-T Pipeline With TPST-4003 RTTNews · Aug 17, 2026
- Rani Therapeutics Appoints Nicholas Maestas CFO Following Sanford Departure RTTNews · Jun 30, 2026
- Tempest Exercises Warrants For $6 Mln In Potential Gross Proceeds; Stock Down RTTNews · May 29, 2026
- Thursday 3/26 Insider Buying Report: RPC, TPSTBNK Invest · Mar 26, 2026
The company
Tempest is a clinical-stage biotechnology company developing next-generation in vivo CAR-T therapies for cancer and autoimmune disease. Tempest's lead product candidate, TPST-4003, combines a clinically supported dual-targeting CD19/BCMA CAR structure with an advanced CD7-targeting delivery system to support broad immune reset across multiple indications. Tempest envisions a world in which immune reset therapies bring safe, effective, and broadly accessible therapeutic options to patients in need.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ-CM
- Region
- North America
- Website
- tempesttx.com
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.